Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 691751 with Itraconazole
NCT02044393Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 691751 in atherosclerosis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve from 0 to Last Quantifiable Concentration and Maximum Measured Concentration. Started Jan 2014; status: completed.
02
Drugs
BI 691751
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02044393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044393.